Keyphrases
Antipsychotics
100%
Cardiovascular Disease
33%
Days of Treatment
16%
Elderly People
100%
Flupentixol
33%
Haloperidol
33%
Head-to-head Comparison
16%
High Risk
16%
Incidence Rate
33%
Long-term Treatment
16%
Major Adverse Cardiovascular Events
100%
Mortality in Elderly
100%
Multivariable
16%
Non-cardiovascular Mortality
100%
Olanzapine
16%
Patients with Cardiovascular Diseases
16%
Poisson Regression
16%
Quetiapine
33%
Randomized Placebo-controlled Trial
16%
Risperidone
33%
Second-generation Antipsychotics
33%
Systematic Difference
16%
Treatment Safety
16%
Treatment-naïve Patients
16%
Ziprasidone
33%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
28%
Antipsychotic
100%
Cardiovascular Disease
100%
Chlorprothixene
28%
Flupentixol
28%
Levomepromazine
28%
Observational Study
14%
Olanzapine
14%
Placebo-Controlled Study
14%
Quetiapine
28%
Risperidone
28%
Ziprasidone
28%
Medicine and Dentistry
Chlorprothixene
28%
Flupentixol
28%
Levomepromazine
28%
Quetiapine
28%